RCUS stock forecast, quote, news & analysis
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases... Show more
Why Arcus Biosciences (RCUS) Stock Is Down -17.9% in the Last 30 Days
Key Takeaways
- Arcus Biosciences (RCUS) has declined roughly 17.9% over the past 30 days, moving from a closing price of $25.95 on September 21 to a latest level near $21.32.
- The slide extends a broader pullback, with the stock down about 28% from levels near $29.50 in late July.
- A sharp mid-September selloff and an October "sell-the-news" reaction to otherwise positive casdatifan data have outweighed a wave of bullish analyst actions.
- Sell-side coverage remains constructive, with several firms raising price targets following the ARC-20 kidney-cancer data readout.
- As a clinical-stage company with no approved products, RCUS remains highly sensitive to binary pipeline and clinical-data catalysts.
Arcus Biosciences (RCUS) Company Overview and Market Position
Arcus Biosciences is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for cancer and inflammatory diseases. Its investigational portfolio includes casdatifan, a HIF-2α inhibitor being studied in clear cell renal cell carcinoma; quemliclustat, a small-molecule CD73 inhibitor; domvanalimab, an anti-TIGIT antibody; zimberelimab, an anti-PD-1 antibody; and etrumadenant, an adenosine receptor antagonist.
The company operates primarily through collaborations and licensing agreements, most notably with Gilead Sciences (GILD). Because Arcus has not yet commercialized an approved product, its valuation is driven by clinical-trial results, regulatory milestones, and partnership economics rather than current product revenue, which contributes to the stock's elevated volatility.
Arcus Biosciences (RCUS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, RCUS has fallen approximately 17.9%, moving from a September 21 close of $25.95 to a latest level near $21.32. The move was not a straight line lower: shares recovered modestly into late September before selling off again through October, punctuated by sharp intraday swings around the company's kidney-cancer data presentation.
The quarterly trend is similarly negative. From levels near $29.48 in late July, the stock has lost roughly 28%, reflecting a sustained de-rating that accelerated in September and continued into October even as analysts raised their price targets. The stock had peaked near $31.57 in late August before the broader retreat took hold.
What Drove RCUS Stock Price in the Last 30 Days
The 30-day decline reflects several overlapping factors. In mid-September, the stock fell sharply over two consecutive sessions, giving back much of the rally that had carried shares to late-August highs. That pullback reset expectations heading into the fall clinical-data season.
In October, the focus shifted to the ARC-20 study, which evaluated casdatifan in clear cell renal cell carcinoma. Data released on October 20 showed a median overall survival of approximately 35 months in a late-line setting, a result analysts described as encouraging relative to existing options, including Merck's (MRK) belzutifan (Welireg). Firms including Mizuho, Citi, Truist, Wedbush, and William Blair responded favorably, with several raising price targets. Despite the positive reception, shares gave back intraday gains and fell further in the following session in a classic "sell-the-news" pattern, as much of the optimism was already reflected in the stock price ahead of the readout.
What Drove RCUS Stock Performance Over the Last Quarter
The three-month decline reflects a combination of elevated expectations building into clinical readouts, profit-taking after the stock's rally to late-August highs, and broader volatility across the clinical-stage biotechnology complex. Heading into the ARC-20 data, RCUS had already pulled back meaningfully from its summer peak, and even favorable survival data failed to sustain a lasting rally.
The quarter also underscored the binary nature of pipeline-stage biotech valuations. With no approved products contributing revenue, single data points and shifts in risk appetite can dominate price action regardless of near-term fundamentals. The competitive backdrop—particularly against Merck's (MRK) established HIF-2α franchise and other immuno-oncology programs—remains a central consideration for investors.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of algorithmic trading bots that have demonstrated notable recent performance. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary widely in strategy, timeframe, and performance metrics, ranging from short-term momentum models to longer-horizon trend-following systems, allowing traders to compare approaches rather than rely on a single signal. For investors tracking volatile names like RCUS, exploring these automated tools can provide an additional, data-driven perspective on market dynamics.
RCUS Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to shape investor sentiment. Additional casdatifan datasets—particularly updates on front-line clear cell renal cell carcinoma and combination studies—represent the most closely watched near-term catalysts. Clinical and regulatory milestones across the domvanalimab, quemliclustat, and zimberelimab programs will also matter, as will quarterly financial results and commentary on cash runway and research spending.
Investors should also monitor competitive dynamics in HIF-2α inhibition and immuno-oncology, any further analyst revisions, and the broader market's appetite for pre-revenue biotechnology companies. As with any clinical-stage developer, trial outcomes remain inherently uncertain, and the stock's direction will continue to hinge on data rather than current financial performance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RCUS in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 21, 2026
RCUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 32 cases where RCUS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for RCUS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 61 cases where RCUS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where RCUS advanced for three days, in 219 of 281 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RCUS as a result. In 76 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for RCUS turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RCUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for RCUS entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. RCUS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.242) is normal, around the industry mean (2.988). P/E Ratio (-4.848) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (25.063) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RCUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which offers pre-clinical drug discovery and development solutions
Industry Biotechnology